Christopher Ryan Sullivan's most recent trade in Avalo Therapeutics Inc was a trade of 138 Common Stock done at an average price of $13.1 . Disclosure was reported to the exchange on June 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.10 per share. | 10 Jun 2026 | 138 | 40,773 | - | 13.1 | 1,808 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2026 | 39,900 | 40,323 | - | 0 | Common Stock | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.88 per share. | 07 May 2026 | 18,606 | 19,029 | - | 9.9 | 183,827 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2026 | 18,606 | 168,094 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.12 per share. | 07 May 2026 | 18,606 | 423 | - | 24.1 | 448,818 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2026 | 47,000 | 116,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 06 May 2026 | 47,000 | 47,423 | - | 8.0 | 377,880 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.55 per share. | 06 May 2026 | 13,834 | 33,589 | - | 18.6 | 256,655 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.28 per share. | 06 May 2026 | 12,347 | 21,242 | - | 19.3 | 238,093 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.37 per share. | 06 May 2026 | 9,219 | 9,323 | - | 21.4 | 197,008 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.57 per share. | 06 May 2026 | 8,900 | 423 | - | 22.6 | 200,913 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.76 per share. | 06 May 2026 | 2,700 | 18,542 | - | 20.8 | 56,052 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.09 per share. | 29 Apr 2026 | 8,458 | 8,880 | - | 13.1 | 110,736 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 13.23 per share. | 29 Apr 2026 | 8,457 | 423 | - | 13.2 | 111,853 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.83 per share. | 01 Apr 2026 | 7,479 | 25,318 | - | 16.8 | 125,841 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.02 per share. | 01 Apr 2026 | 6,200 | 19,118 | - | 17.0 | 105,553 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.57 per share. | 01 Apr 2026 | 1,780 | 17,338 | - | 17.6 | 31,270 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.86 per share. | 01 Apr 2026 | 500 | 32,797 | - | 15.9 | 7,929 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 24,200 | 41,538 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2026 | 24,200 | 24,200 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.89 per share. | 28 Mar 2026 | 8,241 | 33,297 | - | 13.9 | 114,467 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.10 per share. | 10 Dec 2025 | 155 | 17,338 | - | 4.1 | 636 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 48,400 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 24,206 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 28 Mar 2025 | 7,285 | 16,921 | - | 8.5 | 61,631 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 163,000 | 163,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 186,700 | 186,700 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 72,600 | 72,600 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.42 per share. | 09 Jun 2023 | 511 | 1,262 | - | 3.4 | 1,748 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Accounting Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 955 | 9,004 | - | 1.6 | 1,499 | Common Stock |